Regeneron Pharmaceuticals (REGN) News Today $743.35 -1.25 (-0.17%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Regeneron Pharmaceuticals Q3 Earnings TranscriptNovember 21 at 7:02 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by BNP PARIBAS ASSET MANAGEMENT Holding S.A.BNP PARIBAS ASSET MANAGEMENT Holding S.A. decreased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 2.9% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 485,847 shares of the biopharmaceuticalNovember 21 at 6:50 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Cornerstone Advisors LLCCornerstone Advisors LLC grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 13.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 6,000 shares of the biopharmaceutical company's stock afNovember 21 at 6:41 AM | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Has $21.56 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Connor Clark & Lunn Investment Management Ltd. boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 115.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,511 shares of the biophNovember 21 at 5:43 AM | marketbeat.comB. Metzler seel. Sohn & Co. Holding AG Buys New Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)B. Metzler seel. Sohn & Co. Holding AG bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 3,360 shares of the biopharmaceutical company's stNovember 21 at 4:52 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. (REGN): Among the Best Genomics Stocks to Buy Right NowNovember 20 at 8:41 PM | msn.comRetireful LLC Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Retireful LLC bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 714 shares of the biopharmaceutical company's stocNovember 20 at 9:05 AM | marketbeat.comRegeneron: The Biotech Stock To Buy NowNovember 19 at 4:13 PM | seekingalpha.comRegeneron Pharmaceuticals, Inc. (REGN) Jefferies London Healthcare Conference (Transcript)November 19 at 4:09 PM | seekingalpha.comHere’s Why Regeneron Pharmaceuticals (REGN) Declined in Q3November 19 at 10:55 AM | msn.comQuest Partners LLC Boosts Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Quest Partners LLC increased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 391.0% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,974 shares of the biopharmaceutical company's stock aNovember 19 at 5:25 AM | marketbeat.comBraun Stacey Associates Inc. Decreases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Braun Stacey Associates Inc. lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 5.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 22,146 sharNovember 18 at 7:21 AM | marketbeat.comSwiss National Bank Has $338.08 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Swiss National Bank boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 0.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 321,600 shares of the biopharmaceutical company's stockNovember 17, 2024 | marketbeat.comSeizert Capital Partners LLC Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Seizert Capital Partners LLC decreased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 11.9% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 45,775 shares of the biopharmaceutical company's stock after sellingNovember 17, 2024 | marketbeat.comRegeneron Pharmaceuticals (NASDAQ:REGN) Shares Unloaded Rep. Greg LandsmanNovember 17, 2024 | americanbankingnews.comCitigroup Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to "Hold"November 17, 2024 | americanbankingnews.comWolfe Research Initiates Coverage of Regeneron Pharmaceuticals (REGN) with Outperform RecommendationNovember 16, 2024 | msn.comMizuho Securities USA LLC Acquires 51,162 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Mizuho Securities USA LLC raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 625.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 59,341 shares of the biopharmaceutiNovember 16, 2024 | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by CIBC Asset Management IncCIBC Asset Management Inc raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 5.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 33,352 shares of the biopharmaceutical company's sNovember 16, 2024 | marketbeat.comRegeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Upgraded by Wolfe ResearchWolfe Research raised Regeneron Pharmaceuticals to a "strong-buy" rating in a research report on Thursday.November 16, 2024 | marketbeat.comRep. Greg Landsman Sells Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) SharesRepresentative Greg Landsman (D-Ohio) recently sold shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). In a filing disclosed on November 14th, the Representative disclosed that they had sold between $1,001 and $15,000 in Regeneron Pharmaceuticals stock on October 15th. The trade occurred in tNovember 16, 2024 | marketbeat.comCitigroup Initiates Coverage of Regeneron Pharmaceuticals (REGN) with Neutral RecommendationNovember 15, 2024 | msn.comSimplify Asset Management Inc. Purchases 3,231 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Simplify Asset Management Inc. grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 50.8% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 9,591 shares of the biopharmaceutical company's stock afteNovember 15, 2024 | marketbeat.comRegeneron Pharmaceuticals (NASDAQ:REGN) Coverage Initiated at Wolfe ResearchWolfe Research initiated coverage on Regeneron Pharmaceuticals in a research report on Friday. They issued an "outperform" rating and a $1,150.00 price target for the company.November 15, 2024 | marketbeat.comING Groep NV Grows Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)ING Groep NV boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 330.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 21,761 shares of the biopharmaceutical comNovember 15, 2024 | marketbeat.comRegeneron Pharmaceuticals (NASDAQ:REGN) Upgraded to "Hold" at CitigroupCitigroup upgraded shares of Regeneron Pharmaceuticals to a "hold" rating in a report on Wednesday.November 15, 2024 | marketbeat.comPress Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticariaNovember 15, 2024 | globenewswire.comDupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)November 15, 2024 | globenewswire.comRegeneron Pharmaceuticals (NASDAQ:REGN) Earns Neutral Rating from Analysts at CitigroupCitigroup initiated coverage on shares of Regeneron Pharmaceuticals in a report on Thursday. They set a "neutral" rating and a $895.00 price target on the stock.November 14, 2024 | marketbeat.com2 Top Growth Stocks to Buy on the DipNovember 14, 2024 | fool.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Victory Capital Management Inc.Victory Capital Management Inc. decreased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 2.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 96,609 shares of the biopharmaceutical company's stockNovember 14, 2024 | marketbeat.comLos Angeles Capital Management LLC Sells 773 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Los Angeles Capital Management LLC lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 30.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,760 shares ofNovember 14, 2024 | marketbeat.comRegeneron announces new, updated data from hematology pipeline at ASHNovember 14, 2024 | markets.businessinsider.comRegeneron initiated with a Neutral at CitiNovember 14, 2024 | markets.businessinsider.comParametrica Management Ltd Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Parametrica Management Ltd bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 1,300 shares of the biopharmaceutical company's stock, valued at approximNovember 13, 2024 | marketbeat.comMQS Management LLC Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)MQS Management LLC bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 728 shares of the biopharmaceutical company's stock, valued at approximaNovember 13, 2024 | marketbeat.comDillon & Associates Inc. Buys 878 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Dillon & Associates Inc. boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 6.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,525 shares ofNovember 13, 2024 | marketbeat.comAigen Investment Management LP Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Aigen Investment Management LP acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 723 shares of the biopharmaceuticNovember 13, 2024 | marketbeat.comRegeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASHNovember 13, 2024 | globenewswire.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by OVERSEA CHINESE BANKING Corp LtdOVERSEA CHINESE BANKING Corp Ltd increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 286.8% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,319 shares of the biopharmaceutical company's stockNovember 13, 2024 | marketbeat.comSumitomo Mitsui Trust Group Inc. Acquires 3,866 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Sumitomo Mitsui Trust Group Inc. grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 1.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 301,508 shares of the biopharmNovember 12, 2024 | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Lessened by Bronte Capital Management Pty Ltd.Bronte Capital Management Pty Ltd. trimmed its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 1.7% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 137,042 shares of the biopharmaceutical company's stock after selling 2,412 shareNovember 12, 2024 | marketbeat.comBaker Avenue Asset Management LP Invests $707,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Baker Avenue Asset Management LP bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the third quarter, according to its most recent disclosure with the SEC. The firm bought 673 shares of the biopharmaceutical company's stock, valued at approximately $707,000. ANovember 12, 2024 | marketbeat.comRegeneron Announces Investor Conference PresentationsNovember 11, 2024 | globenewswire.com1,269 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Acquired by Catalytic Wealth RIA LLCCatalytic Wealth RIA LLC acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 1,269 shares of the biopharmaceutical compaNovember 11, 2024 | marketbeat.comWe Think Regeneron Pharmaceuticals (NASDAQ:REGN) Can Manage Its Debt With EaseNovember 10, 2024 | finance.yahoo.comAssetmark Inc. Has $109.31 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Assetmark Inc. increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 8.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 103,980 shares of the biopharmaceutical compaNovember 9, 2024 | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by AIA Group LtdAIA Group Ltd grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 6.2% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 10,641 shares of the biopharmaceutical company's stock after acquiring an additional 621 sNovember 8, 2024 | marketbeat.comSummit Global Investments Purchases 2,195 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Summit Global Investments lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 22.7% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 11,868 shares of the biopharmaceutical company's stock afterNovember 8, 2024 | marketbeat.comARK Investment Management LLC Sells 714 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)ARK Investment Management LLC cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.5% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,151 shares of the biopharmaceutical company's stockNovember 8, 2024 | marketbeat.com Get Regeneron Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners… Claim your FREE 2024 Gold Guide REGN Media Mentions By Week REGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. REGN News Sentiment▼0.940.46▲Average Medical News Sentiment REGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. REGN Articles This Week▼3217▲REGN Articles Average Week Get Regeneron Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BeiGene News Royalty Pharma News Catalent News Amgen News Vertex Pharmaceuticals News Gilead Sciences News Alnylam Pharmaceuticals News Biogen News United Therapeutics News Incyte News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:REGN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regeneron Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
